<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104102">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766661</url>
  </required_header>
  <id_info>
    <org_study_id>TURNBULL-BCN-01</org_study_id>
    <secondary_id>PR174/11</secondary_id>
    <nct_id>NCT01766661</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal</brief_title>
  <acronym>TURNBULL-BCN</acronym>
  <official_title>Prospective Multicenter Randomized Controlled Trial Comparing Postoperative Complications and Quality of Life in Low Rectal Cancer Surgery Between Coloanal Anastomosis and Lateral Ileostomy Versus Two-Stage Turnbull-Cutait Coloanal Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to decrease the morbidity by 30% using the Turnbull-Cutait
      procedure in comparison to the standard surgery for low rectal cancer. The investigators
      compare quality of life, faecal incontinence and recurrence of neoplasm in patients who
      received standard colo-anal anastomosis with protective ileostomy or two-staged
      Turnbull-Cutait colo-anal anastomosis after Low Anterior Resection for rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anastomotic leak represents the most frequent complication after rectal cancer surgery and a
      lateral covering ileostomy is usually performed to reduce its incidence. Other important
      consequences of rectal cancer surgery are alterations in bowel habits and function and a
      negative impact on quality of life. This prospective, randomized, multicenter and controlled
      trial compares post-operative complications, quality of life, faecal incontinence and
      recurrence rate in patients treated for low rectal cancer with colo-anal anastomosis
      protected by a lateral ileostomy or with a two-staged Turnbull-Cutait colo-anal anastomosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>post-operative morbidity</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>by COREFO questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal incontinence</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>by Wexner Incontinence Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local and/or distant recurrence of neoplasm</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Rectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Coloanal anastomosis with  ileostomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hand-sewn coloanal anastomosis protected by a loop ileostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two stage Turnbull-Cutait anastomosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hand-sewn coloanal anastomosis</intervention_name>
    <description>After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.</description>
    <arm_group_label>Coloanal anastomosis with  ileostomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two staged Turnbull-Cutait procedure</intervention_name>
    <description>After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.</description>
    <arm_group_label>Two stage Turnbull-Cutait anastomosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultralow anterior rectal resection with total mesorectal excision</intervention_name>
    <description>Standard ultralow anterior rectal resection with total mesorectal excision</description>
    <arm_group_label>Coloanal anastomosis with  ileostomy</arm_group_label>
    <arm_group_label>Two stage Turnbull-Cutait anastomosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with adenocarcinoma of the lower-middle third of the rectum proctoscopy
             established by rigid proctoscopy, with histological confirmation and candidates of
             colo-anal anastomosis;

          -  Patients over 18 years and under 75 years, who can tolerate neoadjuvant and surgical
             treatment;

          -  Patients who undergo an ultra-low anterior rectal resection with total mesorectal
             excision and nerve and sphincter-sparing with curative intention

          -  Any extension of the primary tumor (T 1-2-3-4) according to the TNM classification;

          -  Patients with or without lymph node metastasis (N - / +) and with or without
             resectable distant metastases;

          -  Patients clinically without fecal incontinence prior to the current illness and with
             a Wexner incontinence Score less than or equal to 5;

          -  Patients ASA I, II or III and adequate hematological, renal and hepatic function;

          -  Patients who signed informed consent.

        Exclusion Criteria:

          -  Altered cognitive state(eg mental retardation or dementia) that prevents
             collaboration in the study or patients who can neither read nor write

          -  Fecal incontinence (Wexner equal to or greater than 6);

          -  Previous surgery or proctological, colonic and anorectal functional disease

          -  Diagnosis of synchronous colorectal or any other active neoplasm;

          -  Patients ASA IV, V;

          -  Pregnancy and lactation;

          -  Rejection of the patient to sign the consent form.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Kreisler Moreno, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Kreisler Moreno, MD, PhD</last_name>
    <phone>+34 932607500</phone>
    <phone_ext>8107</phone_ext>
    <email>ekreisler@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Donostia University Hospital</name>
      <address>
        <city>San Sebastian</city>
        <state>Guip√∫zcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JOSEMARIA ENRIQUEZ NAVASCUES, MD, PhD</last_name>
      <phone>+34 943007000</phone>
      <email>JOSEMARIA.ENRIQUEZNAVASCUES@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loris Trenti, MD</last_name>
      <phone>+34 932607500</phone>
      <phone_ext>8107</phone_ext>
      <email>loris.trenti@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Universitary Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloy Espin, MD, PhD</last_name>
      <phone>+34 934 89 30 00</phone>
      <email>eespin@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Girona University Hospital</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Codina Cazador, MD, PhD</last_name>
      <phone>+34 972 94 02 00</phone>
      <email>acodinac.girona.ics@gencat.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Sebastiano Biondo</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
